Overview Financials News + Filings Key Docs Charts Ownership Insiders
All All (ex-4s) 10-K 10-Q 8-K 3,4,5 Proxy Prospectus Other
Tags Appointed CFO Quarterly results CC transcript
|
PALISADE BIO, INC. (CUR)
|
Create: Alert |
All | News | Filings
Date Filed | Type | Description |
10/05/2023 |
4
| Finley John David (CEO, CFO, Director) has filed a Form 4 on PALISADE BIO, INC.
Txns:
| Paid exercise price by delivering 397 shares
@ $0.5501, valued at
$218.4 Exercised 1,309 options to buy
@ $0 |
|
09/29/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
09/29/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
08/14/2023 |
4
| Finley John David (CEO, CFO, Director) has filed a Form 4 on PALISADE BIO, INC.
Txns:
| Paid exercise price by delivering 1,040 shares
@ $0.7, valued at
$728 Exercised 3,475 options to buy
@ $0 |
|
08/10/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
07/06/2023 |
4
| Finley John David (CEO, CFO, Director) has filed a Form 4 on PALISADE BIO, INC.
Txns:
| Paid exercise price by delivering 389 shares
@ $1.764, valued at
$686.2 Exercised 1,309 options to buy
@ $0 |
|
06/09/2023 |
8-K
| Director compensation was amended/approved
Docs:
|
"Palisade Bio, Inc. 2021 Equity Incentive Plan Adopted by the Board of Directors: February 9, 2021 Approved by the Stockholders: April 9, 2021 Amended by the Stockholders: November 18, 2021 Amended by the Stockholders: June 8, 2023 1. General. Plan Purpose. The Company, by means of the Plan, seeks to secure and retain the services of Employees, Directors and Consultants, to provide incentives for such persons to exert maximum efforts for the success of the Company and any Affiliate and to provide a means by which such persons may be given an opportunity to benefit from increases in value of the Common Stock through the granting of Awards. Available Awards. The Plan provides for the grant of the following Awards: Incentive Stock Options; Nonstatutory Stock Options; SARs; Restricted Stock Awa...",
"Palisade Bio, Inc. 2021 Employee Stock Purchase Plan Adopted by the Board of Directors: February 9, 2021 Approved by the Stockholders: April 9, 2021 Amended by the Stockholders: June 8, 2023 1. General; Purpose. The Plan provides a means by which Eligible Employees of the Company and certain Designated Companies may be given an opportunity to purchase shares of Common Stock. The Plan permits the Company to grant a series of Purchase Rights to Eligible Employees under an Employee Stock Purchase Plan. In addition, the Plan permits the Company to grant a series of Purchase Rights to Eligible Employees that do not meet the requirements of an Employee Stock Purchase Plan. The Plan includes two components: a 423 Component and a Non-423 Component. The Company intends the 423 Component to qualify ..." |
|
05/11/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
04/28/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
04/27/2023 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
04/21/2023 |
S-1
| Form S-1 - General form for registration of securities under the Securities Act of 1933: |
04/21/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
04/21/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
04/21/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
04/05/2023 |
4
| McRae Robert Curtis (COO) has filed a Form 4 on PALISADE BIO, INC.
Txns:
| Paid exercise price by delivering 270 shares
@ $2, valued at
$540 Exercised 655 options to buy
@ $0 |
|
04/05/2023 |
4
| Finley John David (CEO, CFO, Director) has filed a Form 4 on PALISADE BIO, INC.
Txns:
| Paid exercise price by delivering 435 shares
@ $2.01, valued at
$874.4 Exercised 1,309 options to buy
@ $0 |
|
04/05/2023 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and E...
Docs:
|
"PRE-FUNDED COMMON STOCK PURCHASE WARRANT palisade bio, inc. Warrant Shares: _________________ Initial Exercise Date: April 5, 2023 Issue Date: April 5, 2023 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT certifies that, for value received, _____________ or its assigns is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after April 5, 2023 and until this Warrant is exercised in full but not thereafter, to subscribe for and purchase from Palisade Bio, Inc., a Delaware corporation , up to ______ shares of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2. Section 1 . Definitions . Capitalized terms used and not otherwise def...",
"COMMON STOCK PURCHASE WARRANT palisade bio, inc. Warrant Shares: _________________ Initial Exercise Date: April 5, 2023 THIS COMMON STOCK PURCHASE WARRANT certifies that, for value received, _____________ or its assigns is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after April 5, 2023 and on or prior to 5:00 p.m. on April 5, 2028 but not thereafter, to subscribe for and purchase from Palisade Bio, Inc., a Delaware corporation , up to ______ shares of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2. Section 1 . Definitions . Capitalized terms used and not otherwise defined herein shall have the meanings set forth ...",
"PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT palisade bio, inc. Warrant Shares: 136,363 Initial Exercise Date: April 5, 2023 THIS PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT certifies that, for value received, Ladenburg Thalmann & Co. Inc. or its assigns is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after April 5, 2023 and on or prior to 5:00 p.m. on April 3, 2028 but not thereafter, to subscribe for and purchase from Palisade Bio, Inc., a Delaware corporation , up to 136,363 shares of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2. This Warrant is issued pursuant to that certain Placement Agency Agreement, b...",
"Fax (805) 553-9783",
"SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement is dated as of April 3, 2023, between Palisade Bio, Inc., a Delaware corporation , and each purchaser identified on the signature pages hereto . WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to an effective registration statement under the Securities Act as to the Registered Shares and Registered Pre-Funded Warrants and an exemption from the registration requirements of Section 5 of the Securities Act contained in Section 4 thereof and/or Regulation D thereunder as to the Unregistered Shares and Unregistered Warrants, the Company desires to issue and sell to each Purchaser, and each Purchaser, severally and not jointly, desires to purchase from the Company, securities of the Company as ...",
"SELLING SHAREHOLDERS The common stock being offered by the selling shareholders are those previously issued to the selling shareholders, and those issuable to the selling shareholders, upon exercise of the warrants. For additional information regarding the issuances of those shares of common stock and warrants, see “Private Placement of Shares of Common Stock and Warrants” above. We are registering the shares of common stock in order to permit the selling shareholders to offer the shares for resale from time to time. Except for the ownership of the shares of common stock and the warrants, the selling shareholders have not had any material relationship with us within the past three years. The table below lists the selling shareholders and other information regarding the beneficial ownership...",
"PLACEMENT AGENCY AGREEMENT _________, 2023 Ladenburg Thalmann & Co. Inc. 640 Fifth Avenue, 4th Floor New York, New York 10019",
"Palisade Bio Announces $6 Million Registered Direct Offering and Concurrent Private Placement Priced Above Market Under Nasdaq Rules" |
|
04/05/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
03/22/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
03/13/2023 |
8-K
| Other Events Interactive Data |
02/14/2023 |
SC 13G
| ARMISTICE CAPITAL, LLC reports a 10% stake in PALISADE BIO, INC. |
02/14/2023 |
SC 13G/A
| Altium Capital Management LP reports a 0% stake in Palisade Bio, Inc. |
02/13/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
02/08/2023 |
4
| Finley John David (CEO, CFO, Director) has filed a Form 4 on PALISADE BIO, INC.
Txns:
| Granted 41,700 options to buy
@ $0 Granted 32,500 options to buy
@ $0 Granted 57,200 options to buy
@ $2.4, valued at
$137.3k
|
|
02/08/2023 |
8-K
| Unregistered Sales of Equity Securities, Departure of Directors or Certain Officers; Election of Directors; Appointment of Ce... |
02/08/2023 |
SC 13G/A
| INTRACOASTAL CAPITAL, LLC reports a 5.7% stake in Palisade Bio, Inc. |
01/25/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
01/24/2023 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
01/13/2023 |
S-1
| Form S-1 - General form for registration of securities under the Securities Act of 1933: |
01/06/2023 |
4
| Finley John David (CEO) has filed a Form 4 on PALISADE BIO, INC.
Txns:
| Granted 5,236 options to buy
@ $0 |
|
01/04/2023 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and E...
Docs:
|
"COMMON STOCK PURCHASE WARRANT palisade bio, inc. Warrant Shares: _______ Initial Exercise Date: ___________, 2022 Issue Date: December ____, 2022 THIS COMMON STOCK PURCHASE WARRANT certifies that, for value received, _____________ or its assigns is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after December ___, 2022 and until this Warrant is exercised in full but not thereafter, to subscribe for and purchase from Palisade Bio, Inc., a Delaware corporation , up to ______ shares of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2. Section 1 . Definitions . Capitalized terms used and not otherwise defined herein shall...",
"COMMON STOCK PURCHASE WARRANT palisade bio, inc. Warrant Shares: _______ Initial Exercise Date: ___________, 2022 Issue Date: December ____, 2022 THIS COMMON STOCK PURCHASE WARRANT certifies that, for value received, _____________ or its assigns is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after December ___, 2022 and until this Warrant is exercised in full but not thereafter, to subscribe for and purchase from Palisade Bio, Inc., a Delaware corporation , up to ______ shares of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2. Section 1 . Definitions . Capitalized terms used and not otherwise defined herein shall...",
"COMMON STOCK PURCHASE WARRANT palisade bio, inc. Warrant Shares: _______ Initial Exercise Date: ___________, 2022 THIS COMMON STOCK PURCHASE WARRANT certifies that, for value received, _____________ or its assigns is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after December ___, 2022 and on or prior to 5:00 p.m. on December ___, 2027 but not thereafter, to subscribe for and purchase from Palisade Bio, Inc., a Delaware corporation , up to ______ shares of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2. Section 1 . Definitions . Capitalized terms used and not otherwise defined herein shall have the meanings set fo...",
"COMMON STOCK PURCHASE WARRANT palisade bio, inc. Warrant Shares: ______________ Initial Exercise Date: _______________, 2022 THIS COMMON STOCK PURCHASE WARRANT certifies that, for value received, _____________ or its assigns is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after December ___, 2022 and on or prior to 5:00 p.m. on December ___, 2027 but not thereafter, to subscribe for and purchase from Palisade Bio, Inc., a Delaware corporation , up to 63,157 shares of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2. Section 1 . Definitions . Capitalized terms used and not otherwise defined herein shall have the mean...",
"Legal Opinion of Silvestre Law Group, P.C",
"SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement is dated as of December 30, 2022, between Palisade Bio, Inc., a Delaware corporation , and each purchaser identified on the signature pages hereto . WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to an effective registration statement under the Securities Act as to the Shares and Registered Pre-Funded Warrants and an exemption from the registration requirements of Section 5 of the Securities Act contained in Section 4 thereof and/or Regulation D thereunder as to the Warrants, the Company desires to issue and sell to each Purchaser, and each Purchaser, severally and not jointly, desires to purchase from the Company, securities of the Company as more fully described in this Agreement. NOW,...",
"SELLING SHAREHOLDERS The common stock being offered by the selling shareholders are those previously issued to the selling shareholders, and those issuable to the selling shareholders, upon exercise of the warrants. For additional information regarding the issuances of those shares of common stock and warrants, see “Private Placement of Shares of Common Stock and Warrants” above. We are registering the shares of common stock in order to permit the selling shareholders to offer the shares for resale from time to time. Except for the ownership of the shares of common stock and the warrants, the selling shareholders have not had any material relationship with us within the past three years. The table below lists the selling shareholders and other information regarding the beneficial ownership...",
"PLACEMENT AGENCY AGREEMENT Ladenburg Thalmann & Co. Inc. 640 Fifth Avenue, 4th Floor New York, New York 10019",
"Palisade Bio Announces $2.5 Million Registered Direct Offering and Concurrent Private Placement Priced Above Market Under Nasdaq Rules",
"Palisade Bio Announces Closing of $2.5 Million Registered Direct Offering and Concurrent Private Placement Priced Above Market Under Nasdaq Rules" |
|
01/04/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
12/16/2022 |
8-K
| Quarterly results |
11/23/2022 |
8-K
| Quarterly results |
|
|
|